Does the Current Evidence for Lecanemab Mechanism Support a Rationale for Continued Lecanemab Dosing?
Dennis J Selkoe, Shobha Dhadda, Michael C Irizarry, Lynn D Kramer · 2025
Read Does the Current Evidence for Lecanemab Mechanism Support a Rationale for Continued Lecanemab Dosing? by Dennis J Selkoe, Shobha Dhadda, Michael C Irizarry, Lynn D Kramer (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712989.txt.
Description
Dennis J Selkoe, Shobha Dhadda, Michael C Irizarry, and Lynn D Kramer review the case, published in 2025, for keeping patients on lecanemab, an antibody drug for Alzheimer disease. The drug targets protofibrils, a toxic mid-size form of amyloid. It binds that form far more strongly than single amyloid units or mature plaques. A large trial found that it slowed decline over eighteen months in early disease.
The authors lay out how the drug works and why stopping early may waste its gains. Alzheimer disease keeps producing amyloid, they argue, so treatment must keep pace. They review the latest data on the drug's action and on tau, the protein that may predict later nerve damage. They also cover the newest rules for diagnosing the disease. Open questions are named plainly. The paper aims to give doctors a reasoned basis for continued dosing.
Catalog record
| CREATOR | Dennis J Selkoe, Shobha Dhadda, Michael C Irizarry, Lynn D Kramer |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |